Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678296 | 0.83 | NISCH (0.39) | DRD2DRD3 | |
| SCHEMBL25155050 | 0.80 | CHRNB2 (0.40) | — | |
| SCHEMBL21679943 | 0.79 | KIT (0.40) | KITRET | |
| SCHEMBL21679936 | 0.79 | RET (0.33) | KITDRD2DRD3RET | |
| SCHEMBL19462890 | 0.79 | RET (0.45) | KITRET | |
| SCHEMBL19458940 | 0.78 | ALDH1A1 (0.44) | KITRET | |
| SCHEMBL25796604 | 0.77 | RET (0.37) | DRD2DRD3RETCYP17A1CYP21A2 | |
| SCHEMBL25155087 | 0.76 | HTR4 (0.36) | KIT | |
| SCHEMBL19458941 | 0.76 | KIT (0.37) | KITRET | |
| SCHEMBL20820713 | 0.76 | RET (0.37) | KITDRD2DRD3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KIT 189/4885DRD2 4568/4885DRD3 4756/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KIT 189/4885DRD2 4568/4885DRD3 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.